An Indian pharmaceutical company announced impressive financial results Wednesday, with fourth-quarter earnings climbing more than 32% compared to the same period last year.
Granules India attributed the strong performance to increased demand for paracetamol and methocarbamol medications across its primary markets, along with recent additions to its product lineup.
The company’s consolidated earnings reached 2.02 billion rupees (approximately $21.3 million) for the quarter ending March 31, up from 1.52 billion rupees in the previous year.
“We delivered a strong performance in Q4 FY26, driven by continued portfolio expansion, disciplined execution, and steady progress across regulatory, compliance, and sustainability initiatives,” stated Managing Director and Chairman Krishna Chigurupati.
Operating revenue increased approximately 23% to 14.71 billion rupees, with North American sales contributing significantly to this growth with a 12% boost. The North American market represents roughly two-thirds of the company’s total sales.
“North America continued to anchor the business as the core growth engine, (while) Europe emerged as a high-momentum market with near doubling performance,” the company reported.
Following the earnings announcement, company shares gained 2% during afternoon trading sessions.
The pharmaceutical manufacturer holds approximately 30% of the worldwide paracetamol market and maintains 10 production facilities across the globe, including seven locations in India, two in the United States, and one in Europe.
The company distributes its medications internationally, reaching customers in the United States, Canada, Latin America, Europe, the Asia-Pacific region, and India.
Financial analysts from Emkay Global predict that growth in fiscal 2027 will likely stem from the expansion of recently launched products, while new controlled drug products expected to launch from fiscal 2028 should provide sustained long-term growth.
The analysts noted that the company has shown better-than-anticipated profit margin stability over the last six quarters, despite facing regulatory challenges at its primary Gagillapur manufacturing site.
Granules has enhanced supervision at its production facilities following U.S. Food and Drug Administration citations for violations at its largest plant, including inadequate record-keeping practices and contamination control problems.
